Research Type: Assessment

Alzheimer’s Disease

Jul 2022 | Assessment

Interventions of Interest: donanemab (Eli Lilly & Co.) lecanemab (Eisai Co., Ltd) aducanumab (Aduhelm™, Biogen) For questions, please contact Kelsey Gosselin, Program Manager, at kgosselin@icer.org. View the Key Stakeholder List. Alzheimer’s disease (AD) is a fatal degenerative brain disease characterized by progressive loss of memory, cognitive skills such as language and problem-solving, and physical function. […]

Beta Thalassemia

Jun 2022 | Assessment

Interventions of Interest: betibeglogene autotemcel (Zynteglo/LentiGlobin, bluebird bio) Beta thalassemia is an inherited blood disorder caused by a genetic mutation of the HBB gene that leads to reduced or absent synthesis of the β-globin proteins of hemoglobin, components of red blood cells responsible for carrying oxygen. When β-globin is markedly reduced or absent, it leads […]

COVID-19

Apr 2022 | Assessment

Interventions of Interest: casirivimab/imdevimab (Ronapreve™, Regeneron) sotrovimab (GlaxoSmithKline and Vir Biotechnology) molnupiravir (Merck) PF-07321332/ritonavir (PAXLOVID™, Pfizer) fluvoxamine (Investigator initiated) ICER is currently conducting a special assessment of outpatient treatments for COVID-19. COVID-19 is an infectious respiratory disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus. As of August 2021, there have been […]

Chemotherapy-Induced Neutropenia

Apr 2022 | Assessment

Interventions of Interest: plinabulin (BeyondSpring Pharmaceuticals) trilaciclib (Cosela™, G1 Therapeutics) Until recently, cytotoxic chemotherapy was the primary form of chemotherapy used to treat cancer, and it remains in widespread use today. Because it targets rapidly dividing cells, one of the common side effects of cytotoxic chemotherapy is low blood cell counts (myelosuppression), including low neutrophil […]

Diabetes: Type 2

Jan 2022 | Assessment

Interventions of Interest: tirzepatide (Eli Lilly) Tirzepatide has a novel dual GIP and GLP-1 receptor agonist mechanism of action and is seen as an add-on type 2 diabetes therapy; tirzepatide would achieve common thresholds for cost-effectiveness if priced between $5,500 – $5,700 per year.  At the January 20 virtual meeting, ICER’s independent appraisal committee will […]

Asthma

Nov 2021 | Assessment

Interventions of Interest: Tezepelumab (Tezpire, Amgen/AstraZeneca) ICER’s Evidence Report Findings: Tezepelumab reduces asthma exacerbations, but there is uncertainty about long-term safety as with all new biologic therapies; tezepelumab would achieve common thresholds for cost-effectiveness if priced between $9,000 – $12,100 per year. Recommendations for fair access include ensuring that all biologic options be available for […]

Hypertrophic Cardiomyopathy

Oct 2021 | Assessment

Interventions of Interest: Mavacamten (MyoKardia and Bristol-Myers Squibb) Concerns about long-term safety influenced majority of independent appraisal committee to vote that evidence is not currently adequate to demonstrate a net health benefit of mavacamten added to background therapy. Using estimates from modeling of short-term benefits, mavacamten does show an overall benefit but would have to […]

Myasthenia Gravis

Sep 2021 | Assessment

Interventions of Interest: Eculizumab (Soliris®, Alexion Pharmaceuticals, Inc.) Efgartigimod (Vyvgart™, argenx) The independent appraisal committee found the evidence is adequate to demonstrate that eculizumab and efgartigimod both provide a net health benefit when compared to conventional therapy alone. According to ICER’s health-benefit price benchmark, eculizumab would need to be priced between $13,200 – $19,400 to be […]

Atopic Dermatitis

Jul 2021 | Assessment

Interventions of Interest: abrocitinib (Cibinqo®, Pfizer) tralokinumab (Adtralza®, LEO Pharma) baricitinib (Olumiant®, Eli Lilly, Incyte Corporation) upadacitinib (Rinvoq®, AbbVie) ruxolitinib (Opzelura™, Incyte Corporation) Atopic dermatitis is a chronic relapsing skin condition associated with dry skin and itching. It is characterized by acute flare-ups of pruritic lesions over dry skin. Atopic dermatitis is a subset of […]

Cardiovascular Disease: Atherosclerosis

Oct 2018 | Assessment

In June 2018, ICER announced its intention to assess the comparative clinical effectiveness and value of canakinumab (Novartis) for cardiovascular risk reduction in people with atherosclerosis. However, in October 2018, when the Food and Drug Administration declined to approve canakinumab’s expanded indication for atherosclerotic cardiovascular disease, ICER announced it would no longer proceed with its value assessment. […]